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Abstract: Pericarditis is a common disorder that has multiple causes and presents in various 
primary-care and secondary-care settings. It is diagnosed in 0.1% of all hospital admissions and 
in 5% of emergency room visits for chest pain. Despite the advance of new diagnostic techniques, 
pericarditis is most commonly idiopathic, and radiation therapy, cardiac surgery, and percutaneous 
procedures have become important causes. Pericarditis is frequently benign and self-limiting. 
Nonsteroidal anti-inflammatory agents remain the first-line treatment for uncomplicated cases. 
Integrated use of new imaging methods facilitates accurate detection and management of compli-
cations such as pericardial effusion or constriction. In this article, we perform a systematic review 
on the etiology, clinical presentation, diagnostic evaluation, and management of acute pericarditis. 
We summarize current evidence on contemporary and emerging treatment strategies.
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Introduction and pathophysiology
Acute pericarditis is due to inflammation of the pericardium and is diagnosed in 
approximately 0.1% of hospital admissions, accounting for up to 5% of emergency 
room visits for chest pain without myocardial infarction.1 In addition, many of the 
electrocardiographic features seen in pericarditis are also evident in acute myocardial 
infarction, whereas treatment of the two conditions differs substantially, making the 
differential diagnosis of paramount importance.
The pericardium is a double-layered fibroserous sac that covers the entire myocardium 
and extends onto the great vessels. Each layer is approximately 1–2 mm thick. The space 
between these layers contains approximately 15–35 mL of serous fluid known as pericardial 
fluid.2 Pericarditis is due to an inflammatory process affecting the inner visceral layer and 
the outer parietal layer of the pericardium. Left undiagnosed and untreated, chronic inflam-
mation of the pericardium can result in complications such as pericardial wall thickening 
and calcification leading to a constrictive pericarditis (Table 1). Acute pericarditis can 
lead to fluid accumulation within the pericardial space known as pericardial effusion. 
In 15% of patients with pericarditis, rapid accumulation of fluid into the pericardial space 
can result in hemodynamic compromise due to impaired filling of intracardiac chambers 
during diastole and lead to cardiac tamponade with hemodynamic compromise, which 
is a life-threatening condition if not recognized and treated promptly.3
Etiology
The etiology of acute pericarditis is at times difficult to identify. As many as 85% of 
acute pericarditis cases are of unknown etiology, labeled as idiopathic origin.4,5 In Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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immunocompetent patients where symptoms may resolve in 
a matter of days, 90% of the time the etiology is thought to 
be viral or idiopathic, and no further workup is needed.6
The cause of inflammation in viral illness is due to the 
replication of the virus in the pericardium which elicits a 
cellular response, which in turn leads to inflammation. Even 
without viral replication, there are a number of viral genomic 
fragments that can also elicit an inflammatory response. 
Moreover, antibodies to these fragments can be found in the 
myopericardium for years and may be an etiology of recur-
rent pericarditis.7 These cases are often preceded by a recent 
flu-like illness or gastrointestinal symptoms and more often 
are secondary to coxsackie B viruses or echoviruses.
However, if tamponade or effusion is present on exami-
nation without signs of inflammation (pain, friction rub) the 
practitioner must consider tuberculosis (TB) or neoplasia in 
the differential diagnosis.8 In Westernized nations, bacterial 
pericarditis is not common, but it is still often seen in the 
developing world, and if untreated is 100% fatal. Even with 
treatment, mortality still approaches 40% due to complica-
tions such as tamponade, bacterial toxicity/sepsis, or other 
infectious complications.9 As the incidence of human immu-
nodeficiency virus (HIV) increases, the incidence of purulent 
pericarditis will likely also increase. In fact, pericarditis is 
the most common cardiovascular manifestation of acquired 
immunodeficiency syndrome (AIDS), occurring in up to 20% 
of patients with HIV/AIDS.10 TB pericarditis is also possible, 
especially in the immunocompromised patient. The classic 
presentation is a subacute illness with fever, effusion, and 
or tamponade. The mortality with TB pericarditis is as high 
as 85%. In developed countries, the incidence is low, but in 
sub-Saharan Africa, the incidence of TB pericarditis reaches 
approximately 70%.11
Neoplasms may also be associated with pericarditis. 
While primary tumors are extremely rare, mesothelioma is 
the most common primary cancerous process. Metastatic 
tumors are 40 times more likely, with the common primary 
lesions being lung, breast, melanoma, lymphoma, and/or 
leukemia.12
Dressler’s syndrome is a postmyocardial infarction 
(MI) finding that develops in weeks to months post-MI or 
cardiac surgery. It is thought to be due to an autoimmune 
reaction mediated by antibodies due to various myocardial 
antigens.1
Renal failure may also cause large pericardial effusions in 
up to 20% of patients. Two basic forms of pericarditis have 
been described in this population; uremic pericarditis, seen 
in 6%–10% of patients with advanced renal failure prior to 
dialysis with a blood urea nitrogen level of .60, and dialysis-
associated pericarditis, which occurs in 13% of patients on 
chronic dialysis.7,13,14
Other etiologies include rheumatologic processes, 
hypothyroidism/myxedema, iatrogenic causes, ie, after open 
heart procedures (valvular operations . coronary artery 
bypass grafts) as well as electrophysiology procedures, and 
radiation therapy for thoracic tumors (Table 2).15,16
Clinical presentation
Acute pericarditis can present with a variety of signs and 
symptoms, which vary depending on the underlying etiol-
ogy and the rapidity with which fluid accumulates (Table 3). 
The classical clinical presentation is a pleuritic chest pain, 
typically retrosternal and positional (exacerbated by lying 
supine and alleviated by sitting up and learning forward). 
Similar to chest pain associated with myocardial infarction, 
pericardial chest pain often radiates to the neck, arms, or even 
the left shoulder. Given that the pericardium is innervated 
by the phrenic nerve, the chest pain due to pericarditis most 
typically radiates to both trapezius muscle ridges.2,18,19 Chest 
pain may be absent in rheumatoid pericarditis, or pericarditis 
due to TB, neoplasm, uremia, and post-radiation. Patients may 
also complain of a viral prodrome of fever, nonproductive 
cough, myalgias, and malaise.
Physical exam may reveal a high-pitched scratchy or 
squeaky sound on the auscultation of the precordium, known 
as a pericardial rub. This is best identified at the left sternal 
border with the diaphragm of the stethoscope during expi-
ration with the patient sitting upright and leaning forward.5 
It is thought to be caused by friction between the visceral 
and parietal pericardial surfaces. Classically, the pericardial 
rub has three distinct components attributed to atrial con-
traction, ventricular contraction, and ventricular relaxation, 
respectively. The rub is triphasic in approximately 50% of 
cases, biphasic in a third of patients, and monophasic in the 
remaining.18,20,21
Table 1 Pericarditis classification scheme3,4
Type Duration  Notes
Acute ,6 weeks effusive versus fibrinous
Subacute 6 weeks–6 months Indolent course
Chronic
Recurrent
.6 months
Intermittent
Incessant
effusive versus adhesive versus 
effusive-adhesive versus constrictive
No symptoms for set time period
Recurrence after discontinuation 
of therapy
Copyright © 2010, wolters Kluwer Health. Adapted with permission from Imazio M, 
Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management 
of pericardial diseases. Circulation. 2010;121(7):916–928.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Given the multitude of differential diagnoses in those 
with chest pain, especially with a pleuritic component, 
the practitioner should take care in trying to distinguish a 
myocardial friction rub from a pleural rub which is timed 
with the respiratory cycle.22 As the severity of disease pro-
cess varies, so does the presentation. If cardiac tamponade is 
present, one can examine for pulsus paradoxus – defined as a 
decrease of systolic blood pressure by more than 10 mmHg 
with inspiration; if constrictive physiology is present, one 
can evaluate for Kussmaul’s sign – defined as an increase 
of the jugular venous pressure with inspiration.23 Another 
sign of tamponade, Beck’s triad, consists of jugular venous 
  distention, hypotension, and muffled heart sounds.24
Laboratory evaluation
Along with physical exam findings, there are some nonspe-
cific laboratory values that may aid in the diagnosis, primarily 
those involved with inflammation. Presence of a leukocytosis, 
elevated erythrocyte sedimentation rate (ESR)/C-reactive 
protein (CRP), and cardiac biomarkers can all aid not only in 
the diagnosis but prognosis and etiology as well.25
There are some lab values that can be useful for 
determining the etiology. Pericardial fluid adenosine 
deaminase and carcinoembryonic antigen can be elevated in 
the case of tuberculosis- and malignancy-related pericarditis, 
respectively.26 If the history is suggestive of a rheumatologic 
etiology, a rheumatoid panel, including antinuclear antibodies 
and rheumatoid factor, may be useful. Moreover, as the 
incidence of AIDS/HIV increases, an HIV screen may be 
of use.27
As discussed above, the presentation of pericarditis can be 
similar to that of a MI. Given that cardiac biomarkers are often 
present in pericarditis, it is important to distinguish between 
the two entities. Anticoagulation and thrombolytic therapy may 
be detrimental in the case of acute pericarditis due to potential 
conversion to hemorrhagic pericardial effusion and tamponade. 
A single center study showed that approximately 20% (40 of 
238) of patients with pericarditis are taken emergently to the 
cardiac catheterization lab or given thrombolytics. However, 
only 35% (14) of these patients who underwent coronary 
angiography had any evidence of cardiac disease, all of which 
was labeled as mild to moderate in nature, highlighting the 
importance of a proper diagnosis.28
Electrocardiographic evaluation
Electrocardiography (ECG) is helpful in the diagnosis of 
acute pericarditis. Classically, it reveals diffuse ST segment 
elevations (concave up) and down-sloping PR segment 
depressions in about 80% of patients. The ECG changes are 
due to superficial myocardial inflammation.29 ECG changes 
evolve in four stages over hours to weeks, and any of these 
manifestations may be present at the time of presentation:
Table 2 etiology of pericarditis
Condition Cause
Infectious pericarditis (2/3 of cases) viral (echovirus, coxsackievirus (most common), influenza, eBv, CMv, adenovirus, varicella,  
rubella, mumps, HBv, HCv, HIv, parvovirus B19, and human herpes virus 6)
Bacterial (tuberculous 4%–5%, Coxiella burnetii, pneumococcosis, meningococcosis,  
gonococcosis, hemophilus, staphylococci, chlamydia, mycoplasma, legionella, leptospira, listeria)
Fungal (histoplasma [more likely in immunocompetent patients], aspergillosis,  
blastomycosis, candida [more likely in immunosuppressed host])
Parasitic (echinococcus, toxoplasma)
Noninfectious pericarditis (1/3 of cases)
  Autoimmune pericarditis (10%) •   Pericardial injury syndromes (post myocardial infarction syndrome, postpericardiotomy 
syndrome, posttraumatic pericarditis including iatrogenic pericarditis from ablations, 
catheterizations)
•   Pericarditis in systemic autoimmune and auto-inflammatory diseases (systemic lupus  
erythematosus, Sjögren syndrome, rheumatoid arthritis, systemic sclerosis,  
systemic vasculitides, Behçet’s syndrome, sarcoidosis, familial Mediterranean fever)
• Autoreactive pericarditis
  Neoplastic pericarditis (5%–7%) • Primary tumors (pericardial mesothelioma)
• Secondary metastatic tumors (lung and breast cancer, lymphoma)
• Metabolic pericarditis (uremia, myxedema)
  Traumatic pericarditis • Direct injury (penetrating thoracic injury, esophageal perforation, iatrogenic)
• Indirect injury (nonpenetrating thoracic injury, radiation injury)
  Drug-related pericarditis • Procainamide, hydralazine, isoniazid, phenytoin, penicillins, doxorubicin, and daunorubicin
Notes: Copyright © 2010, wolters Kluwer Health. Adapted with permission from Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the 
management of pericardial diseases. Circulation. 2010;121(7):916–928.
Abbreviations: CMv, cytomegalovirus; eBv, epstein–Barr virus; HBv, hepatitis B virus; HCv, hepatitis C virus; HIv, human immunodeficiency virus.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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a.  Stage 1 – diffuse ST segment elevations that are concave 
up in all leads except V1 and aVR, with down-sloping PR 
segment depression in most leads but particularly leads II, 
aVF, and V4–V6, but not in leads V1 and aVR.
b.  Stage 2 – ST and PR segments normalize and T waves 
flatten.
c.  Stage 3 – diffuse T wave inversion.
d.  Stage 4 – T waves return to baseline, and resolution of 
the changes.30,31
The time frame of the evolution of these ECG changes 
was described in 50 patients with acute pericarditis. Stage 1 
was noted after only 0.5 days of symptoms, and initially 
only PR segment depressions were seen. Stage 2 occurred 
approximately 1.5 days from symptoms onset and showed 
both ST changes as well as PR segment depressions. Stage 3 
occurred 9.1 days from presentation, whereas resolution 
or stage 4 was noted on days 10–11.29 Electrical alternans, 
defined as beat-to-beat oscillating QRS axes seen on ECG, 
can indicate a large pericardial effusion due to rotation of the 
heart in an increased amount of pericardial fluid.
Application of imaging  
in acute pericarditis
Various imaging modalities aid the clinician in accurate 
diagnosis. If there is greater than 250 mL of fluid in the peri-
cardial space, the chest X-ray will demonstrate an enlarged 
cardiac silhouette.3
The 2004 European Society of Cardiology (ESC) guidelines 
recommend echocardiography if pericarditis is suspected since 
the presence of a pericardial effusion can aid in the management 
and diagnosis.7 Depending on the size of the effusion, small 
effusions are denoted as ,10 mm of fluid, moderate effusions 
as 10–20 mm of fluid, and severe effusions when .20 mm of 
fluid is present.32 While an echo will demonstrate an effusion in 
approximately 60% of cases, it is not required for diagnosis.33
Diagnostic tools
A number of studies have examined the usefulness of 
pericardial biopsy or pericardiocentesis to aid in the 
diagnosis. In patients with large effusions resulting in 
hemodynamic compromise, emergent pericardiocentesis 
should be performed. However, when done for diagnostic 
purposes, pericardiocentesis yielded a specific diagnosis in 
only 6% of cases. Therapeutic pericardiocentesis performed 
in the setting of cardiac tamponade can yield a diagnosis up 
to 29% of the time.4 Pericardial biopsy has similar results. 
When done for diagnostic reasons, the yield is often only 5% 
versus a yield of 54% in cases where biopsy was part of the 
treatment procedure and or in recurrent cases.4 Overall, the 
etiology is determined in only about a quarter of patients.
Clinical course
Current European Guidelines suggest that all patients 
with newly diagnosed acute pericarditis be admitted for 
observation.7 However, the decision to admit these patients 
has been debated in a number of papers by various authors. 
Some would suggest that patients with fevers .38°C, those 
with subacute onset, failure of treatment of nonsteroidal 
anti-inflammatory drugs (NSAIDs) after 1 week, immuno-
suppression, trauma, on anticoagulation therapy, with known 
neoplasm, suspected myopericarditis, severe effusion/tam-
ponade, or hemodynamic instability should be considered 
high risk and admitted.17,33,34 Risk factors associated with a 
poor prognosis include female gender (hazard ratio [HR] of 
1.65), large effusion/tamponade (HR 2.51), aspirin or NSAID 
failure in setting of tamponade (HR 5.5).35 Some may con-
sider elevated troponins as a risk factor for complication, and 
while in the setting of acute ECG changes it made lead to a 
cardiac catheterization, overall the prognostic implication is 
benign. It should be noted that elevated troponins are more 
likely associated with myopericarditis, which is considered 
a high risk factor.36,37
Treatment
The treatment of acute pericarditis is largely anecdotal and 
empirical due to a lack of randomized trials. To date only one 
major published guideline exists, the European Guidelines 
published in 2004. As discussed above, the vast majority of 
cases are idiopathic or viral in nature, and no specific treat-
ment is needed. But, in the few instances where a specific 
etiology can be identified, the treatment should be geared 
towards the underlying process.
The mainstay of therapy is NSAIDs (Class I per the 
ESC guidelines) especially in low-risk patients; with low 
risk being defined as immunocompetent patients with 
a presumed viral or idiopathic cause. There are limited 
to no data on the exact dose and treatment course using 
Table 3 Diagnostic criteria7,17,22,33 (Two of the four should be 
present)
Typical chest pain
Pericardial friction rub
Suggestive eCG changes 
New or worsening pericardial effusiona
Note: aThis is debatable and may be used to confirm diagnosis, but lack of pericardial 
effusion does not exclude diagnosis.
Abbreviation: eCG, electrocardiography.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
139
Treatment of acute pericarditis
NSAIDs. It should be noted that a high anti-inflammatory 
dose needs to be prescribed; aspirin of 2–4 g/day, ibuprofen 
1200–1800 mg/day, indomethacin of 75–150 mg/day.38 If the 
patient has underlying heart disease and is already on an 
aspirin for primary or secondary prevention, it would be a 
reasonable choice to continue in higher doses. However, if 
not already on aspirin, ibuprofen may be the preferred agent 
due to a low rate of side effects, favorable impact on coronary 
blood flow, as well as a large dosing range.7,25
Indomethacin may be used in the management of acute 
pericarditis. However, indomethacin should not be used in 
patients with known or suspected coronary artery disease due 
to its vasoconstrictory effect.39 In those patients with renal 
disease, a small trial demonstrated that 25 mg of indometha-
cin 4 times daily in patients on dialysis had no overall effect 
on symptoms or natural history of the disease.40 Ketorolac, an 
NSAID with an intravenous formulation, was used in a small 
study in patients with pericarditis associated with Dressler’s 
syndrome, idiopathic pericarditis, or post cardiotomy and 
demonstrated symptomatic relief with fast onset, but no com-
ment was made on the natural history of pericarditis.41
When using NSAIDs, it is important to consider the 
medications’ side effects including but not limited to plate-
let inhibition, renal effects, as well as gastrointestinal (GI) 
upset/bleeding. The American College of Gastroenterology 
has identified a number of risk factors of GI toxicity related 
to NSAID use: age .60 years, history of a previous adverse 
event, high dose NSAIDs, concurrent use of glucocorticoids, 
or use of concurrent anticoagulants.42 Hence, a number of the 
authors of various trials including a NSAID treatment arm 
have recommend GI protection with 20 mg/day of omepra-
zole.33 The length of treatment is debatable. Some would 
recommend following CRP as an indicator for response to 
treatment as it can represent the level of inflammation. CRP 
is recommended instead of ESR given lack of confounding 
factors and faster changes.38 Full dose anti-inflammatory 
NSAIDs should be continued for a total of 7–14 days, and 
then after CRP normalizes, a taper can be started.
The addition of colchicine has been shown to decrease 
the duration of symptoms as well as the rate of recurrence of 
acute pericarditis. A dose of 0.5 mg daily has been recom-
mended by the ESC guidelines. Colchicine is already used 
in a number of other inflammatory diseases such as gout or 
serositis associated with familial Mediterranean fever.43 The 
drug was first used in 1987 for recurrent pericarditis, and since 
then a number of retrospective studies have been published to 
examine the effect of colchicine on pericarditis.13,44–50 On the 
basis of these studies, the ESC guidelines have recommended 
colchicine as Class I for recurrent pericarditis and optional, 
but probably useful in acute pericarditis (Class IIa). The 
COlichicine for acute PEricarditis (COPE) trial demonstrated 
that the addition of colchicine at 0.6 mg twice daily for 
3 months to standard therapy with aspirin reduced the 
recurrence rate from 33% in the aspirin-only group to 11% 
in the aspirin + colchicine group.48 Furthermore, there was 
a longer event-free survival in the colchicine group as well 
as a faster resolution of symptoms. It would appear that 
colchicine is a useful adjunct therapy to NSAIDs as well as 
steroids to prevent recurrence of pericarditis. The COlchicine 
for REcurrent pericarditis (CORE) trial49 has confirmed the 
value of colchicine in the treatment of recurrent pericarditis, 
demonstrating that the addition of colchicine decreased the 
recurrence rate compared with conventional treatment in 
patients with a first episode of recurrent pericarditis.50 Both 
trials also highlighted the previous use of corticosteroids as 
an independent risk factor for higher rate of recurrence. There 
are a number of ongoing clinical trials also examining the 
effect of the addition of colchicine to conventional treatment 
in acute pericarditis.43,51–54 As with NSAIDs, colchicine also 
has a number of side effects, including dose-related GI side 
effects in 10%–15% of patients. Renal insufficiency can raise 
the levels of colchicine; hence lower doses may be indicated 
in this patient population.55
Corticosteroids are another anti-inflammatory agent 
that can be used in patients who cannot tolerate NSAIDs or 
colchicine. However, various experts as well as the European 
guidelines suggest limiting their use in acute pericarditis, 
mainly due to a strong concern for increasing the rate 
of recurrence. Yet, these agents are still administered in 
60%–90% of patients in most series.56 While steroids can 
often provide fast symptomatic relief, they are often not used 
correctly or tapered appropriately.57–59 Furthermore, there are 
data to suggest steroid use is an independent risk factor for 
recurrent pericarditis.17,33,35,55,57 This is likely due to the fact 
that the majority of cases are viral or idiopathic in nature and 
corticosteroids are immunosuppressive and affect the body’s 
response to viral illness. One study does suggest benefit from 
high-dose corticosteroids.60 In this study, 12 patients with 
relapse of pericarditis after receiving low-dose steroids were 
given high doses of prednisone 1–1.5 mg/kg/day for 4 weeks 
followed by a 2-month taper. Of note, once the taper was 
started, patients were started on a 5-month course of aspirin 
at 1.6 g/day during the steroid taper and 0.8 g/day after the 
taper. All but one patient had no relapse. Initially, it would 
appear that high-dose steroids show benefit; however, all 
the patients were on NSAIDs (a Class 1 indication per ESC Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
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guidelines), so it would be difficult to determine the exact 
effect of the steroids. Hence, it is reasonable to use steroids 
in patients with rheumatologic causes of pericarditis or, as 
mentioned previously, to those with NSAID intolerance or 
failure.38,57
There has been one study to specifically look at high- 
versus low-dose steroids. In this group, 100 patients with 
recurrent pericarditis were treated with low-dose prednisone 
0.2–0.5 mg/kg/day versus 1 mg/kg/day. Each dose was con-
tinued for 4 weeks and then tapered. Patients treated with 
high dose steroids showed a higher rate of steroid related side 
effects, as well as, interestingly, a higher rate of relapse.61 This 
would lead one to believe that low-dose steroids are better, but 
again the data are limited and there is a specific need for larger 
trials. Currently it would appear that if steroids are needed, 
a low-dose regimen of 0.2–0.5 mg/kg/day (or high doses if 
required to control symptoms) be used for 2–4 weeks until 
CRP resolves, and then to begin a taper with the addition of 
an NSAID or colchicine if tolerated (Table 4).62
As with NSAIDs, corticosteroids carry their own adverse 
reaction potential, including issues with glycemic control, 
cushingoid effects, or immunosuppression. Often overlooked 
is the need for supplementation of vitamin D and calcium or 
need for bisphosphonates while on steroids.17
Due to its lack of systemic side effects, intrapericardial 
steroids, triamcinolone in particular, has shown some promise 
in the treatment of acute pericarditis. Per the ESC 2004 guide-
lines, intracardiac steroids are a Class IIa indication with 
B level of evidence. In one study designed to examine the 
efficacy of intrapericardiac steroids in those with autoreactive 
effusions, 260 patients underwent extensive workup for peri-
carditis. Of these 260 patients, 84 underwent intrapericardial 
instillation of triamcinolone. These patients were divided 
into two groups; 50 received 600 mg/m2/24 h, and the other 
received 300 mg/m2/24 h. Intrapericardial administration of 
triamcinolone resulted in symptomatic improvement and 
prevented effusion recurrence in 92.6% of group 1 (600 mg) 
versus 86.7% in groups 2 (300 mg) after 3 months, and 86% in 
group 1 versus 82% in group 2 at 1 year. Moreover, there were 
no documented treatment-related complications, although 
the group receiving the higher dose did have a higher rate 
of transient Cushing’s syndrome.63 In a second study from 
a registry of 136 patients undergoing pericardiocentesis, 
29 patients were selected, 14 with autoimmune pericarditis 
and 15 with neoplastic effusions as treatment arms. Of the 
14 patients with autoimmune pericarditis, 1 g of crystalloid 
triamcinolone was given and prevented recurrence at 3 months 
in 13 of the 14 cases, and 12 of the 14 at 1 year. In patients 
with cancer, 50 mg of cisplatin was used and prevented recur-
rence in all 15 patients at 3 months and 14 of 15 patients at 
6–12 months. Of note, mortality was high in this case series; 
47% at 3 months and 80% at 6 months, but it was due to 
noncardiac tumor progression.64 There are some data sug-
gesting that intrapericardial cisplatin may be more effective 
in patients with secondary lung cancer and that thiotepa may 
be more effective in patients with breast cancer.7,55 Tetracy-
cline has been used as a sclerosing agent and to prevent fluid 
reaccumulation in the setting of malignancy. However, there 
is a high rate of side effects despite an 85% rate of success.7 
Overall, there are limited data on intrapericardial agents and 
further trials are needed.
While there may be a role for other immunomodulating 
agents such as methotrexate, cyclosporine, and azathiopine, 
their use in pericarditis is extremely rare and should be 
tailored to the rare individualized patient.
The role of pericardiectomy, pericardial window, and 
other interventional techniques is reserved primarily for 
those with resistant recurrent cases.7,17 Limited data exist 
Table 4 Medical therapy for acute pericarditis
Drug (duration prior to taper) Starting dose (dose range) Tapering every 1–2 weeks after symptom resolution
Aspirin (1–2 weeks) 750–1000 mg TID (2–4 g/day) 750–1000 mg BID then 750–1000 mg/day
Ibuprofen (1–2 weeks) 600 mg TID (1600–3200 mg) 600 mg BID or 400 mg BID then 600 mg qday
Indomethacin (1–2 weeks) 50 mg TID 75–150 mg/day
Prednisone (2 weeks) 75–150 mg
0.2–0.5 mg/kg/day
1.0–1.5 mg/kg/daya
Reduce total dose by 25 mg/day/week
If .50 mg, reduce by 10 mg/day every 1–2 weeks
If 50–25 mg, reduce 5–10 mg every 1–2 weeks
If 25–15 mg, reduce 2.5 mg/day every 2–4 weeks
If ,15 mg, reduce 1.0–2.5 mg/day every 2–6 weeks
Colchicineb (3 months for  
acute pericarditis)
0.5 mg BID 
0.5 mg/day if ,70 kg
Optional for acute cases, consider 2–4 weeks tapering
Notes: Doses are all estimated for anti-inflammatory effect. Limited data on tapering and schedule may be changed on an individual basis. aHigh dose versus low dose; likely 
benefit from low dose with or without adjuvant therapy; bColchicine is used as adjuvant therapy; no data for primary use exists yet. Copyright © 2010, wolters Kluwer 
Health. Adapted with permission from Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. Circulation. 
2010;121(7):916–928.
Abbreviations: BID, 2 times per day; TID, 3 times per day; qday; every day. Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
141
Treatment of acute pericarditis
for pericardiectomy, and actual efficacy is questioned. The 
current indications should be determined by expert opinion 
or in those patients presenting with constrictive pericarditis 
(unless newly diagnosed and hemodynamically stable).
Conclusion
Pericarditis is a cause of chest pain with various etiologies. 
As our diagnostic abilities of chest pain improve, so too will 
our diagnosis of pericarditis. The treatment of pericarditis 
has not changed for a number of years. The current trends 
of tapering NSAIDs, and various other anti-inflammatories, 
primarily colchicine, are changing the way we approach 
treatment of primary pericarditis.
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